TME Pharma Completes Funding, Bolsters Cash Position

TME Pharma announced the completion of its August funding round, adding €500,000 to its cash reserves, bringing the total to €2.35 million. The company is focusing on cost efficiency to support development of cancer and eye disease therapies.







